National Blood Authority’s Management of the Manufacture and Supply of Domestic Fractionated Blood Plasma Products
The objective of this audit is to examine the effectiveness of the National Blood Authority’s management of the manufacture and supply of domestic fractionated blood plasma products.
The ANAO proposes to examine:
- Was there appropriate planning in place to support strategic procurement for the manufacture and supply of domestic fractionated blood plasma products?
- Did the procurement process support the achievement of value for money?
- Were effective contract management and monitoring arrangements established to ensure the delivery of the National Fractionation Agreement for Australia?
Contribute to this audit
We anticipate accepting contributions to this audit until Sunday 29 November 2020.
Work program portfolio
This in-progress performance audit is featured in 1 annual audit work program portfolio: